Tarsus Reports Full-Year 2022 Financial Results and Recent Business Achievements
Engaging with more than two-thirds of key optometrists and/or ophthalmologists, and top payers on Demodex blepharitis in anticipation of TP-03 August 25, 2023 PDUFA
Completed enrollment of Ersa, a Phase 2a trial evaluating TP-03 for MGD with topline data expected in 2H 2023 and initiated Galatea Phase 2a trial evaluating TP-04 for Rosacea
Cash runway anticipated into at least 2H 2026 to support planned TP-03 commercialization and continued pipeline development
IRVINE, Calif., March 13, 2023 (GLOBE NEWSWIRE) -- Tarsus Pharmaceuticals, Inc. (NASDAQ: TARS), whose mission is to focus on unmet needs and apply proven science and new technology to revolutionize treatment for patients, starting with eye care, today announced financial results for the full-year ended December 31, 2022, and recent business achievements.
“In 2022 we had a clear vision to transform eyelid health, starting with the development of our novel investigational treatment for Demodex blepharitis, a disease that impacts millions of Americans. This year, we continue to focus on this unique opportunity, and we are actively educating the market on the disease as we move closer to our PDUFA target action date,” said Bobak Azamian, M.D., Ph.D., Chief Executive Officer and Chairman of Tarsus. “Alongside our efforts in Demodex blepharitis, we’re working to advance our pipeline, including the initiation of our Phase 2 trial in rosacea, and our planned Phase 2a data readouts from our Lyme disease prevention and MGD-related trials in the second half of 2023. We remain well capitalized and positioned to deliver on our commitment to uniquely change the landscape of eyelid health.”
Recent Business Highlights and Corporate Update
•New Drug Application (NDA) for TP-03 for the treatment of Demodex blepharitis accepted by the U.S. Food and Drug Administration (FDA); Prescription Drug User Fee Act (PDUFA) target action date of August 25, 2023
•Launched an Awareness, Trial and Usage (ATU) market research survey of ~250 optometrists and ophthalmologists to capture and analyze awareness and likelihood to prescribe a potential prescription therapeutic for Demodex blepharitis
◦More than 90% indicated they would prescribe an FDA approved therapeutic for Demodex blepharitis
•Engaged and educated more than two-thirds of target Eye Care Practitioners (ECPs) on the disease, identification and diagnosis of Demodex blepharitis
◦“Look at the Lids” disease education campaign has generated more than 125K unique website visits and nearly 2M digital/media impressions
•Actively engaging with top commercial and Medicare accounts, educating on the potential value of prescription therapies for Demodex blepharitis
•Completed enrollment of Ersa, a Phase 2a trial evaluating TP-03 for the potential treatment of Meibomian Gland Disease (MGD) with topline data expected in the second half of 2023
•Initiated Galatea, a Phase 2a trial evaluating TP-04, a novel gel formulation of lotilaner, for the potential treatment of rosacea
◦Demodex mites are highly prevalent in rosacea patients and may contribute to the pathology of disease
◦TP-04 is being developed to eradicate Demodex mites, a potential root cause of disease
◦Positive Phase 1 data shows TP-04 was well tolerated and safety data supports progression to Phase 2a
•Cash runway anticipated into at least the second half of 2026
Anticipated 2023 Clinical and Regulatory Milestones
| Program | Milestone | Anticipated Indication | H1 2023 | H2 2023 | ||||||||||
| TP-04 | Initiated Phase 2a (Galatea) | Rosacea | ||||||||||||
| TP-05 | Topline Phase 2a Data (Carpo) | Lyme disease prevention | ● | |||||||||||
| TP-05 | Initiate Phase 2b | Lyme disease prevention | ● | |||||||||||
| TP-03 | Approval and Launch | Demodex blepharitis | ● | |||||||||||
| TP-03 | Topline Phase 2a (Ersa) | Meibomian Gland Disease | ● | |||||||||||
Full-Year 2022 Financial Results
•Full year TP-03 out-license revenue for greater China territory was $25.8 million, compared to $57.0 million in 2021
•Full year net loss was $62.1 million, compared to $13.8 million in 2021
•Full year research and development expenses were $42.6 million, compared to $41.7 million in 2021
•Full year general and administrative expenses were $44.9 million, compared to $25.4 million in 2021
•As of December 31, 2022, cash, cash equivalents and marketable securities were $217.0 million
About Tarsus Pharmaceuticals, Inc.
Tarsus Pharmaceuticals, Inc. applies proven science and new technology to revolutionize treatment for patients, starting with eye care. Tarsus is advancing its pipeline to address several diseases with high unmet need across a range of therapeutic categories, including eye care, dermatology, and infectious disease prevention. Tarsus is studying three investigational medicines in clinical trials. Its lead product candidate, TP-03, is a novel therapeutic which has demonstrated positive results in two pivotal trials for the treatment of Demodex blepharitis, and the New Drug Application for TP-03 has been accepted by the U.S. Food & Drug Administration (FDA) with a PDUFA target action date of August 25, 2023. TP-03 is also being developed for the potential treatment of Meibomian Gland Disease, and is currently being studied in a Phase 2a clinical trial. In addition, Tarsus is developing TP-04 for the treatment of Rosacea and TP-05, an oral tablet for the potential prevention of Lyme disease. TP-04 and TP-05 are both currently being studied in Phase 2a clinical trials to evaluate safety, tolerability, and proof-of-activity.
Forward-Looking Statements
Statements in this press release about future expectations, plans and prospects, as well as any other statements regarding matters that are not historical facts, may constitute “forward-looking statements.” These statements include statements regarding the potential approval and commercialization of TP-03, the market size for TP-03, TP-04, and TP-05, including our ability to educate the market about Demodex blepharitis, the timing, objectives, and results of the clinical trials, anticipated regulatory and development milestones, the initiation of Phase 2 studies for Lyme disease prevention and the treatment of rosacea, our cash runway expectations, our ability to continue investing in our business, future events and Tarsus’ plans for and the anticipated benefits of its product candidates including TP-03, TP-04 and TP-05, and the quotations of Tarsus’ management. The words, without limitation, “believe,” “contemplate,” “continue,” “could,” “estimate,” “expect,” “intend,” “may,” “might,” “plan,” “potential,” “predict,” “project,” “should,” “target,” “will,” or “would,” or the negative of these terms or other similar expressions are intended to identify forward-looking statements, although not all forward-looking statements contain these or similar identifying words. Actual results may differ materially from those indicated by such forward-looking statements as a result of various important factors. Important factors that could cause actual results to differ materially from those in the forward-looking statements include: Tarsus’ ability to obtain regulatory approval for and successfully commercialize TP-03 for the treatment of Demodex blepharitis, Tarsus has incurred significant losses and negative cash flows from operations since inception and anticipates that it will continue to incur significant expenses and losses for the foreseeable future; Tarsus may need to obtain additional funding to complete the development and any commercialization of its product candidates, if approved; Tarsus is heavily dependent on the success of its lead product candidate, TP-03 for the treatment of Demodex blepharitis; the COVID-19 pandemic may affect Tarsus’ ability to initiate and complete preclinical studies and clinical trials, disrupt regulatory activities, disrupt manufacturing and supply chain or have other adverse effects on Tarsus’ business and operations; even if TP-03, TP-04, TP-05, or any other product candidate that Tarsus develops receives marketing approval, Tarsus may not be successful in educating healthcare professionals and the market about the need for treatments specifically for Demodex blepharitis, MGD, rosacea, Lyme disease prevention, and/or other diseases or conditions targeted by Tarsus’ products; the development and commercialization of Tarsus products is dependent on intellectual property it licenses from Elanco Tiergesundheit AG; Tarsus will need to develop and expand the company and Tarsus may encounter difficulties in managing its growth, which could disrupt its operations; the sizes of the market opportunity for Tarsus’ product candidates, particularly TP-03 for the treatment of Demodex blepharitis and MGD, TP-04 for the treatment of Rosacea, as well as TP-05 for the prevention of Lyme disease, have not been established with precision and may be smaller than estimated; the results of Tarsus’ earlier studies and trials may not be predictive of future results; any termination or suspension of, or delays in the commencement or completion of, Tarsus’ planned clinical trials could result in increased costs, delay or limit its ability to generate revenue and adversely affect its commercial prospects; and if Tarsus is unable to obtain and maintain sufficient intellectual property protection for its product candidates, or if the scope of the intellectual property protection is not sufficiently broad, Tarsus’ competitors could develop and commercialize products similar or identical to Tarsus’ products. Further, there are other risks and uncertainties that could cause actual results to differ from those set forth in the forward-looking statement and they are detailed from time to time in the reports Tarsus files with the Securities and Exchange Commission, including Tarsus’ Form 10-K for the year ended December 31, 2021 filed on March 14, 2022 and the most recent Form 10-Q quarterly filing filed with the SEC, which Tarsus incorporates by reference into this press release, copies of which are posted on its website and are available from Tarsus without charge. However, new risk factors and uncertainties may emerge from time to time, and it is not possible to predict all risk factors and uncertainties. Accordingly, readers are cautioned not to place undue reliance on these forward-looking statements. Any forward-looking statements contained in this press release are based on the current expectations of Tarsus’ management team and speak only as of the date hereof, and Tarsus
specifically disclaims any obligation to update any forward-looking statement, whether as a result of new information, future events or otherwise.
Media Contact: | |||||
Adrienne Kemp | |||||
| Sr. Director, Corporate Communications | |||||
(949) 922-0801 | |||||
| akemp@tarsusrx.com | |||||
Investor Contact: | |||||
| David Nakasone | |||||
| Head of Investor Relations | |||||
| (949) 620-3223 | |||||
| DNakasone@tarsusrx.com | |||||
TARSUS PHARMACEUTICALS, INC.
STATEMENTS OF OPERATIONS AND COMPREHENSIVE LOSS
(In thousands, except share and per share amounts)
(Unaudited)
| Year Ended December 31, | |||||||||||
| 2022 | 2021 | ||||||||||
| Revenues: | |||||||||||
| License fees | $ | 23,893 | $ | 53,067 | |||||||
| Collaboration revenue | 1,923 | 3,960 | |||||||||
| Total revenues | 25,816 | 57,027 | |||||||||
| Operating expenses: | |||||||||||
| Cost of license fees and collaboration revenue | 955 | 2,075 | |||||||||
| Research and development | 42,624 | 41,712 | |||||||||
| General and administrative | 44,949 | 25,397 | |||||||||
| Total operating expenses | 88,528 | 69,184 | |||||||||
| Loss from operations before other income (expense) and income taxes | (62,712) | (12,157) | |||||||||
| Other income (expense): | |||||||||||
| Interest income | 3,499 | 36 | |||||||||
| Interest expense | (2,199) | — | |||||||||
| Other income (expense), net | 86 | (73) | |||||||||
| Unrealized loss on equity investments | (268) | (591) | |||||||||
| Change in fair value of equity warrants issued by licensee | (501) | (987) | |||||||||
| Total other income (expense), net | 617 | (1,615) | |||||||||
| Loss from operations before income taxes | (62,095) | (13,772) | |||||||||
| Benefit (provision) for income taxes | 4 | (55) | |||||||||
| Net loss | $ | (62,091) | $ | (13,827) | |||||||
| Other comprehensive loss: | |||||||||||
| Unrealized loss on marketable securities and cash equivalents | (74) | — | |||||||||
| Comprehensive loss | $ | (62,165) | $ | (13,827) | |||||||
| Net loss per share, basic and diluted | $ | (2.52) | $ | (0.67) | |||||||
| Weighted-average shares outstanding, basic and diluted | 24,619,700 | 20,554,086 | |||||||||
TARSUS PHARMACEUTICALS, INC.
BALANCE SHEETS
(In thousands, except share and par value amounts)
(Unaudited)
| December 31, | |||||||||||
| 2022 | 2021 | ||||||||||
| ASSETS | |||||||||||
| Current assets: | |||||||||||
| Cash and cash equivalents | $ | 71,660 | $ | 171,332 | |||||||
| Marketable securities | 145,366 | 483 | |||||||||
| Other receivables | 3,582 | 92 | |||||||||
| Prepaid expenses | 4,767 | 4,045 | |||||||||
| Total current assets | 225,375 | 175,952 | |||||||||
| Property and equipment, net | 957 | 755 | |||||||||
| Operating lease right-of-use assets | 575 | 1,074 | |||||||||
| Long-term investments | 371 | — | |||||||||
| Other assets | 585 | 1,126 | |||||||||
| Total assets | $ | 227,863 | $ | 178,907 | |||||||
| LIABILITIES AND STOCKHOLDERS' EQUITY | |||||||||||
| Current liabilities: | |||||||||||
| Accounts payable and other accrued liabilities | $ | 9,910 | $ | 8,680 | |||||||
| Accrued payroll and benefits | 5,519 | 2,798 | |||||||||
| Total current liabilities | 15,429 | 11,478 | |||||||||
| Term loan, net | 19,434 | — | |||||||||
| Other long-term liabilities | 100 | 699 | |||||||||
| Total liabilities | 34,963 | 12,177 | |||||||||
| Commitments and contingencies | |||||||||||
| Stockholders’ equity: | |||||||||||
Preferred stock, $0.0001 par value; 10,000,000 shares authorized; no shares issued and outstanding | — | — | |||||||||
Common stock, $0.0001 par value; 200,000,000 shares authorized; 26,727,458 shares issued and outstanding at December 31, 2022; 20,726,580 shares issued and 20,698,737 outstanding, which excludes 27,840 shares subject to repurchase at December 31, 2021 | 5 | 4 | |||||||||
| Additional paid-in capital | 301,732 | 213,398 | |||||||||
| Accumulated other comprehensive loss | (74) | — | |||||||||
| Accumulated deficit | (108,763) | (46,672) | |||||||||
| Total stockholders’ equity | 192,900 | 166,730 | |||||||||
| Total liabilities and stockholders’ equity | $ | 227,863 | $ | 178,907 | |||||||